Oklahoma City, OK Clinical Trials Report — July 2026

Oklahoma City participants should act quickly if they match a study nearing its enrollment deadline: 28 recruiting trials are expected to close within the next 90 days, including 2 that accept healthy volunteers. The city currently has 595 recruiting trials across 232 research facilities, so contacting a site early may provide more options before studies reach their enrollment targets.

July brought 6 new trials, down from 11 in June and May’s 11. The new-study mix includes three drug trials, one behavioral study, one device study, and one dietary-supplement study. University of Oklahoma sponsors four of the new openings, while Evopoint Biosciences Inc. and Karuna Therapeutics, Inc., a Bristol Myers Squibb company, sponsor one each.

Closing windows for Oklahoma City patients and volunteers

Breast and endometrial cancer have the most closing-soon opportunities, with 2 trials each. Other affected conditions include acute myeloid leukemia, advanced solid tumors, aggression, psychomotor agitation, alcohol use disorder, alcohol use complicating pregnancy, Alzheimer disease, and AML. The dataset lists 28 closing-soon trials overall, but only 2 are identified as accepting healthy volunteers.

• Breast cancer (2 trials)
• Endometrial cancer (2 trials)
• Acute myeloid leukemia (1 trial)
• Advanced solid tumor (1 trial)
• Aggression (1 trial)
• Psychomotor agitation (1 trial)
• Alcohol use disorder (1 trial)
• Alcohol use complicating pregnancy, unspecified trimester (1 trial)
• Alzheimer disease (1 trial)
• AML (1 trial)

People considering one of these studies should ask the research facility whether enrollment is still open, since a projected closing date can change when a trial reaches its participant goal. Healthy volunteers have fewer immediate choices: 37 healthy-volunteer trials are recruiting in Oklahoma City overall, but only two of the studies nearing closure accept healthy participants.

New Phase 2 and Phase 3 studies to watch

Several July openings stand out because of their size, sponsor, or development stage. The most advanced is Karuna Therapeutics’ Phase 3 schizophrenia study, while the University of Oklahoma added several research projects spanning cancer detection, cannabis-use decisions, and endometrial cancer treatment.

• NCT07686263, “Relapse Prevention Trial Evaluating KarXT Treatment in Schizophrenia,” is a Phase 3 study sponsored by Karuna Therapeutics, Inc., a Bristol Myers Squibb company. It plans to enroll 472 participants and evaluates whether KarXT can help prevent relapse in people with schizophrenia.
• NCT07737795, “Evaluating the Addition of OK-1 Weekly Paclitaxel in Patients With Endometrial Cancer,” is a Phase 2 University of Oklahoma study with planned enrollment of 66 participants. It evaluates OK-1 combined with paclitaxel for advanced or recurrent endometrial cancer.
• NCT07732686, “Analysis of Breath Volatile Organic Compounds Using Mass Spectrometry,” is sponsored by the University of Oklahoma and plans to enroll 2,000 participants. Researchers are studying whether breath-based volatile organic compound patterns could support earlier cancer detection.
• NCT07701304, “Testing Warning Labels for Retail Cannabis Products Using a Discrete Choice Experiment,” is a University of Oklahoma behavioral study involving 450 participants. It examines reactions to different cannabis packaging and health-warning designs.

New conditions represented this month include bladder, breast, colon, endometrial, head and neck, lung, and hepatocellular cancers, along with metastatic pancreatic cancer, cannabis use, and decision making. Six new trials include older adults. None include children, one is female-only, and none is male-only.

Where Oklahoma City has the deepest access

The University of Oklahoma Health Sciences Center is the city’s largest research hub, with 188 recruiting trials. Mercy Hospital Oklahoma City follows with 58, while the University of Oklahoma has 29. These sites provide the broadest starting points for patients searching across multiple conditions.

• University of Oklahoma Health Sciences Center (188 trials)
• Mercy Hospital Oklahoma City (58 trials)
• University of Oklahoma (29 trials)
• Research Site (19 trials)
• OU Health Stephenson Cancer Center (16 trials)
• Stephenson Cancer Center (15 trials)
• Oklahoma Medical Research Foundation (13 trials)
• Hightower Clinical (12 trials)
• The University of Oklahoma Health Sciences Center (11 trials)
• Oklahoma Heart Hospital (9 trials)
• Lynn Health Science Institute (7 trials)
• Integris Southwest Medical Center (6 trials)

For cancer studies, OU Health Stephenson Cancer Center and Stephenson Cancer Center are particularly prominent, while the University of Oklahoma Health Sciences Center and Mercy Hospital Oklahoma City offer broader clinical research access. Patients should confirm the exact facility name and study contact because related institutions may appear as separate entries.

Healthy-volunteer opportunities and travel options

One of the 6 new July trials accepts healthy volunteers. Eligibility still depends on each protocol’s age range, health requirements, medication restrictions, and other screening criteria. Healthy adults interested in contributing to research should search the full pool rather than focus only on July’s openings, since 37 healthy-volunteer trials are recruiting locally.

Participants willing to travel can also check other Oklahoma locations. Recruiting trials are listed in Norman, Stillwater, and Tulsa, with 1 trial in each city. These nearby options may be useful when an Oklahoma City study has strict eligibility requirements or closes before a screening visit can be scheduled.

New openings have fluctuated during 2026, reaching 8 in February, 9 in March and April, 7 in May, 11 in June, and 6 in July. As summer progresses, people with breast or endometrial cancer, those considering the closing healthy-volunteer studies, and adults interested in the new University of Oklahoma or Phase 3 schizophrenia research should contact local sites soon while the current opportunities remain available.